A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with advanced Hepatocellular Carcinoma (HIMALAYA)
Latest Information Update: 26 Jul 2024
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms HIMALAYA
- Sponsors AstraZeneca
- 14 Nov 2023 Results (Data-cut off was 23 January 2023 )of updated 4-year OS analysis , presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 29 Jun 2023 Results presented AstraZeneca in the Media Release.
- 29 Jun 2023 Results presented AstraZeneca in the Media Release.